Source:http://linkedlifedata.com/resource/pubmed/id/18304964
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0034656,
umls-concept:C0038952,
umls-concept:C0085533,
umls-concept:C0183683,
umls-concept:C0229601,
umls-concept:C0344211,
umls-concept:C0439234,
umls-concept:C0439859,
umls-concept:C0746319,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1516213,
umls-concept:C1521721,
umls-concept:C1522577
|
| pubmed:issue |
6
|
| pubmed:dateCreated |
2008-5-29
|
| pubmed:abstractText |
Investigation of high-dose chemotherapy (HD-CT) compared with standard-dose chemotherapy (SD-CT) as adjuvant treatment in patients with primary breast cancer and >/=10 axillary lymph nodes. From November 1993 to September 2000, 307 patients were randomized to receive after four cycles of epirubicin (90 mg/m(2)), cyclophosphamide (600 mg/m(2)) i.v. (every 21 days) and either HD-CT of cyclophosphamide (1500 mg/m(2)), thiotepa (150 mg/m(2)) and mitoxantrone (10 mg/m(2)) i.v. for four consecutive days followed by stem cell transplantation or a SD-CT of three cycles CMF (cyclophosphamide 500 mg/m(2), methotrexate 40 mg/m(2), 5-fluorouracil 600 mg/m(2), i.v. on day 1 and 8, respectively, every 28 days). After a median follow-up of 6.1 years, 166 events with respect to event-free survival (EFS) (SD-CT: 91, HD-CT: 75) have been observed. The hazard ratio of HD-CT versus SD-CT is estimated as 0.80 [95% confidence interval (0.59, 1.08)], P = 0.15. The trend to a superiority of HD-CT as compared with SD-CT with respect to EFS seems to be more pronounced in premenopausal patients as compared with postmenopausal patients and in patients with tumor grade 3 as compared with patients with tumor grade 1/2. With a follow-up of 6 years, there was a trend in favor of HD-CT with respect to EFS not being significant. A proper meta-analysis needs to be undertaken for an evaluation of subgroups of patients who might benefit from HD-CT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1569-8041
|
| pubmed:author |
pubmed-author:BerdelW EWE,
pubmed-author:FrickhofenNN,
pubmed-author:JonasPP,
pubmed-author:KoenigsmannMM,
pubmed-author:KrögerNN,
pubmed-author:KrügerWW,
pubmed-author:KreienbergRR,
pubmed-author:MöbusVV,
pubmed-author:MetznerBB,
pubmed-author:PossingerKK,
pubmed-author:SchmoorCC,
pubmed-author:SchumacherMM,
pubmed-author:ThielEE,
pubmed-author:WandtHH,
pubmed-author:ZanderA RAR
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1082-9
|
| pubmed:meshHeading |
pubmed-meshheading:18304964-Adult,
pubmed-meshheading:18304964-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18304964-Breast Neoplasms,
pubmed-meshheading:18304964-Chemotherapy, Adjuvant,
pubmed-meshheading:18304964-Cyclophosphamide,
pubmed-meshheading:18304964-Dose-Response Relationship, Drug,
pubmed-meshheading:18304964-Female,
pubmed-meshheading:18304964-Follow-Up Studies,
pubmed-meshheading:18304964-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:18304964-Humans,
pubmed-meshheading:18304964-Lymph Nodes,
pubmed-meshheading:18304964-Lymphatic Metastasis,
pubmed-meshheading:18304964-Middle Aged,
pubmed-meshheading:18304964-Mitoxantrone,
pubmed-meshheading:18304964-Neoplasm Staging,
pubmed-meshheading:18304964-Prospective Studies,
pubmed-meshheading:18304964-Survival Analysis,
pubmed-meshheading:18304964-Thiotepa,
pubmed-meshheading:18304964-Transplantation, Autologous
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up.
|
| pubmed:affiliation |
Center of Oncology, Clinic for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|